

Amendments to the Claims

The following Listing of Claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1-14. (CANCELED)

15. (Currently Amended) The method of claim 27, wherein [[a]] the therapeutically synergistic inhibitory effective amount of (E)-4-[2-[2-[N-acetyl-N-[(p-methoxyphenyl)sulfonyl]amino]phenyl]ethenyl]pyridine 1-oxide or a pharmaceutically acceptable salt thereof is administered simultaneously with cisplatin.

16. (Currently Amended) The method of claim 27, wherein [[a]] the therapeutically synergistic inhibitory effective amount of (E)-4-[2-[2-[N-acetyl-N-[(p-methoxyphenyl)sulfonyl]amino]phenyl]ethenyl]pyridine 1-oxide or a pharmaceutically acceptable salt thereof is administered in combination with cisplatin sequentially.

17-26. (Canceled)

27. (Currently Amended) A method for treating a patient suffering from at least one malignant tumor selected from the group consisting of blood cancer, leukemia, human colon adenocarcinoma, gastrointestinal cancer, lung cancer, breast cancer, and prostate cancer, the method comprising administering a therapeutically synergistic inhibitory effective amount of (E)-4-[2-[2-[N-acetyl-N-[(p-methoxyphenyl)sulfonyl]amino]phenyl]ethenyl]pyridine 1-oxide or a pharmaceutically acceptable salt thereof in combination with cisplatin, wherein the therapeutically synergistic inhibitory effective amount of (E)-4-[2-[2-[N-acetyl-N-[(p-methoxyphenyl)sulfonyl]amino]phenyl]ethenyl]pyridine 1-oxide with cisplatin gives a synergistic inhibitory effect.